spacer
home > news
INDUSTRY NEWS AND PRESS RELEASES
 

OMRON halves cost to cobot palletise solving pharma industry’s workforce challenges

Responding to the pharmaceutical industry’s end-of-line labour challenges including staff shortages, social distancing measures and self-isolation, OMRON UK will debut its game changing cobot palletiser, the RB1200, at PPMA Show 2021. Thanks to OMRON’s renowned iAutomation proprietary technology, the cobot system boasts a 50% cost saving, rapid delivery within weeks and plug-and-play system architecture to help pharma manufacturers of all budgets and sizes immediately de-risk their line against today’s unprecedented labour challenges. More>>

 
phone 01908 258253
email uk@eu.omron.com
web www.industrial.omron.co.uk
email Opal Drive, Fox Milne, Milton Keynes, MK15 0DG
 

Qatar Airways Cargo Becomes a Member of Cool Chain Association

The airline along with Cool Chain Association members will deliver concrete solutions to improve the cool chain The membership aligns with the airline’s sustainability programme, WeQare as Cool Chain Association aims to reduce food wastage through cool chain integrity and stakeholder involvement Qatar Airways Cargo has extended its cool chain industry partnerships by joining Cool Chain Association (CCA), a non-profit organisation, effective 28 July 2021. More>>

 
phone +974 40222072
email qrmedia@qatarairways.com.qa
web www.qatarairways.com
 

Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe

SOMERSET, N.J. – July 21, 2021 – Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply. More>>

 
phone +1 888 765 8846
email info@catalent.com
web www.catalent.com
email 14 Schoolhouse Road, Somerset 08873 NJ , USA
 

Brain Mapping Pioneer Omniscient Neurotechnology Raises AUD 40 Million in Series B Financing

Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, today announced the completion of an AUD 40 million Series B financing round. The funding was led by family offices and high-net worth individuals, including Hancock Prospecting’s Executive Chairman Mrs. Gina Rinehart, and prominent fund manager Will Vicars. More>>

 
email contact@o8t.com
web www.o8t.com
email Level 10, 580 George Street Sydney NSW 2000
 

Almost 70% of Doctors Say Covid-19 Vaccine Rates Would Be Higher If They Could Administer to Their Own Patients, New Survey Shows

Sermo’s COVID-19 Real Time Barometer survey suggests patients would be more open to vaccine if received from a physician they know and trust

With variants on the rise and the continued need for vaccinations, a new global survey of physicians finds that many doctors believe that they may be the key to boosting vaccination rates as they are an important source of information, comfort, and reassurance for COVID-19 vaccine-reluctant patients. More>>

 
web https://www.sermo.com/
 

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy

SOUTH SAN FRANCISCO – July 14, 2021 – Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, has joined its Early Access Partnership Program (EAPP). Poseida is the third organization to participate in Cellares’ EAPP, following industry partner PACT Pharma and academic partner Fred Hutchinson Cancer Research Center. More>>

 
phone (833) 235-5273
web www.cellares.com
email South San Francisco, California
 

Klöckner Pentaplast Launches Its 2020 Sustainability Report

London, UK – 19 July 2021 – Klöckner Pentaplast (kp or the company), a global leader in high barrier protective packaging solutions, today announced the release of its 2020 Sustainability Report, detailing its progress and commitment to key sustainability initiatives. The report provides details of performance relating to topics that are material to its business and has been prepared in accordance with the Global Reporting Initiative (GRI) Standards. More>>

 
phone +49.2602.915.0
web https://www.kpfilms.com/en/
email Klöckner Pentaplast Group, P.O. Box 11 65 56401, Montabaur, Germany
 

Rentschler Biopharma Expands Production of Highly Complex Antibodies at German Site

Rentschler Biopharma expands production capacity with 2,000-liter bioreactor to address increasing demand for complex antibodies, a class of biopharmaceutical drugs with continued high potential

Laupheim, Germany, June 30, 2021 – Antibody therapies have become an integral part of treating serious and rare diseases. "It is all the more important that we have a high level of expertise in drug development as well as in bioprocess development and production of therapeutic antibodies," said Dr. Frank Mathias, CEO of Rentschler Biopharma SE... More>>

 
phone +49 7392 701-0
email info@rentschler-biopharma.com
web www.rentschler.de
email Erwin-Rentschler-Str. 21, 88471 Laupheim
 

CARMAT Announces the First Human Implant of its Total Artificial Heart in the United States

The implant was performed at Duke University Hospital, one of the largest U.S. cardiology centers

Paris, July 15, 2021 - 7 am CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS). More>>

 
phone +33(0)1 39 45 64 50
email contact@carmatsas.com
web www.carmatsa.com/en
email 36, avenue de l’Europe Immeuble l’Etendard 78140 Vélizy-Villacoubla
 

Ashfield Launches Cell & Gene Therapy Commercialization Network, EmerGENE

14th July 2021 Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries. More>>

 
web www.ashfieldhealthcare.com
 
 
spacer
News and Press Releases

Bio-Rad Launches Its Reliance SARS-CoV-2/FluA/FluB RT-PCR Assay Kit in Europe

HERCULES, Calif.– July 14, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
More info >>


White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement